For a great many people who start a GLP-1 medication, this is not the first thing they have tried. It is closer to the last. Behind them is often a long line of attempts: the diets that worked and then unravelled, the programs, the years of personal effort, the slow accumulation of evidence, gathered over time, that their body does not respond to the things that are supposed to work. By the time the medication enters the picture, it is carrying a particular weight. It is the thing that is finally meant to be different.
That framing is worth saying out loud, because it changes what is at stake. When something feels like the last option, the cost of it going badly is not just the weight. It is what the person concludes about themselves when it does. And the version of this treatment most likely to go badly is the one most commonly sold: the medication on its own, handed over with a prescription and very little else.
This is the case for why the plan built around the medication matters at least as much as the medication, and why getting that wrong does a particular kind of harm.
The medication is doing less of the work than it looks
Start with what the medication actually does, because it is easy to overestimate. These drugs are genuinely effective. They also have two well-documented limits that the marketing tends to skip.
The first is that the effect is held in place by the drug, not installed permanently by it. When treatment stops, the biology it was managing comes back. In the large trials, people who stopped regained the majority of what they had lost over the following year, and the metabolic improvements faded with the weight. The drug manages the condition while it is present, it does not cure it and leave. That is not a flaw in the medication, it is simply what it is, but it means the loss is borrowed against continued treatment unless something else is built to hold it.
The second limit is subtler and less known. The body adapts to the medication itself, over time, even at a steady dose. The slowing of the stomach that drives a lot of the early fullness desensitises over weeks to months. The appetite suppression tends to soften, and weight loss commonly plateaus somewhere around the six-to-twelve-month mark as the body adjusts. The drug’s own grip loosens as the body learns to work around it. This is why a maintenance dose, while a genuinely useful tool, is not a set-and-forget answer either, the same adaptation applies. Leaning the entire result on the molecule, at any dose, is leaning on a lever the body is quietly working to neutralise.
Put those two facts together and a conclusion follows that the standalone-prescription model ignores entirely: the medication buys a window of biological help, real but time-limited and partly self-eroding, in which something more durable has to be built. The drug opens the door. It does not walk you through it.
What has to be built in that window
What holds weight off, when the pharmacology is doing less than it was, is the unglamorous set of things the medication’s quiet period gives a person the chance to establish.
Habits that survive a softer appetite signal, eating patterns and routines that hold up when the drug is no longer doing all the appetite management for you. Muscle, preserved through resistance training during a phase when rapid loss otherwise strips it, which protects the metabolic rate that makes maintenance possible. And the psychological side, which the evidence is increasingly clear about. People who maintain their loss tend to develop a realistic, reasonably kind view of their changed body, while those who regain tend to show worsening body image, more self-judgment, and more withdrawal. Structured psychological support, cognitive behavioural and acceptance-based approaches in particular, produces a real if modest improvement in maintenance over going it alone, and it works through exactly the levers, motivation, self-efficacy, the all-or-nothing thinking that converts one slip into total collapse, that decide whether a person keeps going.
None of these is delivered by a prescription. They are delivered by a plan: a prescriber who adjusts and monitors, allied health input for movement and nutrition, mental health support where it is needed, and a regular GP who knows the whole person and stays in the loop. The medication makes all of it easier by quietening the appetite while it is being built. That is the right way to use the window the drug provides, and it is precisely what the standalone model does not offer.
Why getting this wrong costs more than money
Here is the part that matters most, and the reason this is not just a question of efficiency.
When someone takes their last, most hopeful attempt, the medication everyone called a breakthrough, and is handed it with no plan around it, the predictable thing happens. The weight responds at first. Then the drug’s effect softens, or the cost becomes unsustainable, or life intervenes, and without the scaffolding to hold the result, the weight returns. From the outside this is an unsurprising outcome of an incomplete treatment. From the inside it is something far worse. It is failing on the thing that was supposed to be different.
That conclusion, “I failed even on the wonder drug,” is more corrosive than any single regain, because of what it does to a person’s sense of what is still possible. A failed diet leaves the belief that the right tool might still be out there. Failing on the tool that was meant to be the answer can take that belief away. It spends something that is very hard to get back: the willingness to try again. For someone who has already spent years of effort and self-blame, that loss of resilience is a genuine harm, and it is one the standalone model produces while appearing to help.
It is worth being precise about where the criticism lands, because it is not a criticism of the medication, which is valuable, nor of telehealth as a way of delivering care, which can be excellent, nor of any individual doctor. It is a criticism of one specific model: the script issued without the surrounding care, the molecule sold as if it were the whole treatment. The problem is not that people are given the drug. It is that they are given only the drug, and then left to conclude, when the incomplete version underdelivers, that the failure was theirs.
The thing worth holding onto
The most useful way to think about a GLP-1 medication is as a powerful, time-limited assist, not a cure and not a standalone solution. It creates a window in which the durable work, habits, muscle, a realistic self-image, the support to sustain all three, can be done with the wind at your back. Used that way, inside a comprehensive plan, it is genuinely transformative. Used alone, it borrows a result against a lever that fades, and risks handing the person the most demoralising outcome of all.
At Anova we think this is the whole point, and the reason the model matters as much as the molecule. A medication this significant deserves to be set up to succeed, which means building the plan that lets its benefits last rather than betting a person’s last and best attempt on the drug alone. For someone for whom this really is the final thing they are willing to try, getting that right is not a nicety. It is the difference between a change that holds and a disappointment they may not recover from.
If you are starting this, or are on it already and wondering what should sit around it, that is a conversation worth having properly, at Anova or with your own GP, rather than assuming the prescription is the whole of the answer.